TrialNet

Eligibility:

• For Individuals who are 2-45 years of age with a parent, child, brother, or sister with T1D.
• For Individuals who are 2-20 years of age with a niece, nephew, aunt, uncle, grandparent, half-sibling or cousin with T1D.

Or

• Are between the ages of 2 and 45 years and have tested positive for at least one type 1 diabetes related autoantibody outside of TrialNet.
• Have not been diagnosed with diabetes.

Purpose: This study helps to identify family members of people with T1D who might have antibodies associated with T1D. Relatives of people with T1D have a 3-4 percent chance of testing positive for antibodies. If participants are found to be antibody positive they will be offered follow up screening and further tests to determine their risk for T1D. Depending on the outcome of those tests, participants may qualify for prevention studies offered by TrialNet.

For more information visit TrialNet on the web. 

Coordinators:  Juanita O'Brian, CMA, CCRC; Henry Rodriguez, MD

Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-9817

 Romosozumab for Children and Adolescents with Osteogenesis Imperfecta

Eligibility:

• Ambulatory children and adolescents, age 5 to < 18 years, including ambulatory with assistance as defined in the pediatric OI population
• Confirmed diagnosis of Osteogenesis Imperfecta types 1, 2, or 4
• 3 or more fractures within the previous 2 years, or 1 or more nonvertebral fracture(s) within the previous 2 years and at least 1 prevalent vertebral fracture, or 2 or more prevalent vertebral fractures.

Purpose: Study to Evaluate Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Coordinator: Ponja Hemphill, RN

Contact: CRC-health@usf.edu